AZP2006
Progressive Supranuclear Palsy (PSP)
Key Facts
About Alzprotect
Alzprotect is a clinical-stage biotech developing AZP2006, a small molecule with a unique, multi-target mechanism for treating neurodegenerative tauopathies. The company's lead program is currently in a Phase 2a platform trial for Progressive Supranuclear Palsy (PSP) and holds Orphan Drug Designation in both the US and EU. With a strategy to advance its candidate through early clinical proof-of-concept and then seek partnerships with larger pharmaceutical companies, Alzprotect is targeting major unmet needs in Alzheimer's, PSP, and potentially Parkinson's disease.
View full company profileAbout Alzprotect
Alzprotect is a clinical-stage biotech developing AZP2006, a small molecule with a unique, multi-target mechanism for treating neurodegenerative tauopathies. The company's lead program is currently in a Phase 2a platform trial for Progressive Supranuclear Palsy (PSP) and holds Orphan Drug Designation in both the US and EU. With a strategy to advance its candidate through early clinical proof-of-concept and then seek partnerships with larger pharmaceutical companies, Alzprotect is targeting major unmet needs in Alzheimer's, PSP, and potentially Parkinson's disease.
View full company profileTherapeutic Areas
Other Progressive Supranuclear Palsy (PSP) Drugs
| Drug | Company | Phase |
|---|---|---|
| PROSPER Study Compound | Ferrer | Phase 2 |
| Not Specified | New Amsterdam Sciences | Pre-clinical |
| PREP/PP2A Modulator Program | Polku Therapeutics | Discovery |
| Undisclosed Tau Immunotherapy | TauC3 Biologics | Pre-clinical |